🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing worldwide, with data suggesting more than 82 million instances each year. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The global health body has classified it as a "critical concern". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists believe that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This medication, which is additionally indicated for UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This approval signifies a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

According to data released by a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This places it at an equal footing with the typical regimen, which involves two antibiotics. The study enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians directly involved have expressed hope. Access to a single-dose, oral treatment such as this is described as a "game-changer" for gonorrhoea control. This is viewed as essential to alleviate the strain of the infection for patients and to prevent the spread of extremely resistant gonorrhoea globally.